Stockscreener 앱 받기
0.571
0.33%
-0.0019
시간 외 거래:
.57
-0.001
-0.18%
전일 마감가:
$0.5729
열려 있는:
$0.5557
하루 거래량:
141.07K
Relative Volume:
1.19
시가총액:
$9.72M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-0.4833
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-10.35%
1개월 성능:
-70.41%
6개월 성능:
-82.10%
1년 성능:
-85.21%
1일 변동 폭
$0.55
$0.58
1주일 범위
$0.5428
$0.6365
52주 변동 폭
$0.50
$5.275
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.571 | 9.72M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com
Offerings News Live Feed - Stock Titan
Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds - Barchart.com
Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com
Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX
In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX
Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister
Intensity Therapeutics plunges on $2.35M public offering - MSN
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus
Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial - Nature
Intensity Therapeutics Inc (INTS)’s stock performance: a year in review - uspostnews.com
Intensity Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
INTS stock touches 52-week low at $1.49 amid market challenges - Investing.com Australia
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Intensity Therapeutics Highlights Cancer Treatment Progress - TipRanks
Is RollsRoyce (RYCEY) Stock Outpacing Its Aerospace Peers This Year? - Yahoo Finance
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why ArcelorMittal (MT) is a Top Value Stock for the Long-Term - Yahoo Finance
Tesla Delays Launch of Cheaper, Stripped-Down Version of Model Y in US - Yahoo Finance
The Zacks Analyst Blog Highlights Affirm, StoneCo, ACI Worldwide, Coinbase Global and OppFi - Yahoo Finance
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - Quantisnow
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Yahoo Finance
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of OD - American Heart Association Journals
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):